The combination of lumacaftor with ivacaftor (LUM/IVA) provided the first positive, albeit modestly so, results in clinical trials addressing the CFTR defect in individuals with the most common CF-causing mutation. The gene discussed is CFTR; the disease is cystic fibrosis.